Find the protocol.
Understand the research.

Also available: 20 mg vial

Retatrutide (LY3437943) is an investigational triple GLP-1/GIP/glucagon receptor agonist. It has been studied in supervised clinical trials but is not an approved medicine. The phase 2 obesity trial used fixed-dose and target-dose arms with gradual escalation every 4 weeks—not automatic weekly increases. For research purposes only.

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a gastric protein sequence studied for tissue-healing and cytoprotective properties. Preclinical models demonstrate accelerated wound repair and anti-inflammatory activity, though human clinical data remain limited to early-phase safety trials and small case reports.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It works synergistically to improve glycemic control and support weight loss by enhancing insulin secretion, delaying gastric emptying, and reducing appetite.

TB-500 is a synthetic peptide fragment corresponding to the active region of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein involved in tissue repair and regeneration.

GHK-Cu is a naturally occurring tripeptide that complexes with copper ions to modulate numerous biological processes. Research has demonstrated its involvement in wound healing through enhanced collagen and decorin gene expression, activation of tissue remodeling pathways, and regulation of genes associated with antioxidant defense and anti-inflammatory responses.

Cited example and evidence context

A research-labelled 80 mg blend combining GHK-Cu, BPC-157, TB-500 and KPV. Research on its individual ingredients does not establish combined human efficacy, compatibility, route or administration schedule.